Open access
Sep 2026
Disitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer
Findings delineate a ferroptosis–ICD–immune axis underlying the antitumor activity of RC48 and support its clinical development as a monotherapy or in combination with immune checkpoint inhibitors for HER2-expressing breast cancer.
Ying-Ying Zhao, Chen-Wei Yuan, Qiong Wu et al.
· Journal of Experimental &... · 0 citations